Indian pharmaceutical major Lupin on Tuesday said it has reached a $90 million settlement with Japan’s Astellas Pharma to resolve a patent dispute related to the bladder disorder drug Mirabegron in the United States. The agreement allows Lupin to continue selling the drug in the US market.
As per an exchange filing, Lupin and its US subsidiary will make a $75 million upfront payment to Astellas, along with per-unit licensing fees on Mirabegron sales through September 2027. Astellas said the settlement brings its litigation with Lupin to a close and that it is assessing the financial impact for the fiscal year ending March 31, 2026.
The dispute stemmed from Lupin’s generic version of Myrbetriq, Astellas’ overactive bladder treatment, following a US court ruling that raised concerns over generic sales. Analysts said the settlement removes legal uncertainty and may delay the entry of additional generic competitors, potentially benefiting Lupin and Zydus Lifesciences. Lupin shares were trading 0.91 per cent higher in early trade.
Lupin, Astellas End US Patent Battle Over Mirabegron
